Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

(2013) Ming-Lung Yu et al.   HEPATOLOGY

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

(2011) Yen-Tsung Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses

(2011) Ming-Lun Yeh et al.   PLoS One

Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis

(2010) HuaBang Zhou et al.   EUROPEAN JOURNAL OF CANCER

HBsAg Profiles in Patients Receiving Peginterferon Alfa‐2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses

(2010) Ming‐Lung Yu et al.   JOURNAL OF INFECTIOUS DISEASES

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus

(2009) Amit G. Singal et al.   Clinical Gastroenterology and Hepatology

Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis

(2009) Ashwani K. Singal et al.   Clinical Gastroenterology and Hepatology

Dual chronic hepatitis B virus and hepatitis C virus infection

(2009) Chun-Jen Liu et al.   Hepatology International

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

(2008) Chun–Jen Liu et al.   GASTROENTEROLOGY

The Secret of Immortal Time Bias in Epidemiologic Studies

(2008) S. Z. Shariff et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY